ADVERTISEMENT
Zydus Lifesciences Q4 Results Review: U.S. Generic Growth Surprises, Says Systematix— Recommends 'Hold'
Systematix tweaks its estimates as it rebuild contribution from gMirabegron for FY26 and incorporate recently approved gCopaxone in our numbers for FY27.
21 May 2025, 09:58 AM IST 
Zydus Lifesciences Ltd.'s US formulations business reported sales of Rs 31,307 million, up 24.1% YoY and 29.9% QoQ. (Photo source: envato)
Zydus Lifesciences’ revenue for Q4 FY25 stood at Rs 65,279 million, up 18.0% YoY and 23.9% QoQ. Ebitda stood at Rs 21,255 mn, up 30.4% YoY and 53.2% QoQ. Ebitda margin at 32.6% was up 310 bps YoY and 623 bps QoQ. PAT stood at Rs 11,709 mn, down 1% YoY but up 14.4% QoQ. PAT margin at 17.9% was down 343 bps YoY and 149 bps QoQ. R&D expense for the quarter was Rs 4,799 mn.
I’m already a Subscriber
To continue reading this storySubscribe to Unlock & Enjoy your
Subscriber-Only benefits
Subscriber-Only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Subscriber-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Subscriber-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
